Molecular classification of hepatocellular carcinoma anno 2011

European Journal of Cancer

Volumn 47, Issue 12, 2011, Pages 1789-1797

  Van Malenstein, H ^a   Van Pelt, J ^a   Verslype, C ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Genetic alterations; Hepatocellular carcinoma; Molecular classification; Targeted therapy; Whole genome profiling

Indexed keywords

AFLATOXIN B1; BETA CATENIN; BRIVANIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; INSULIN; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; PROTEIN P53; RAPAMYCIN; RETINOBLASTOMA BINDING PROTEIN 1; SOMATOMEDIN B RECEPTOR; SORAFENIB; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR 2; WNT PROTEIN;

CANCER CLASSIFICATION; CANCER GROWTH; CANCER STEM CELL; CELL NUCLEUS; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CLINICAL DECISION MAKING; CODON; CYTOPLASM; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE ACTIVATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HEPATITIS C VIRUS; HETEROZYGOSITY LOSS; HUMAN; LIVER; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; ONCOGENE C MYC; ONCOGENE K RAS; OVERALL SURVIVAL; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANTINEOPLASTIC AGENTS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; MICROARRAY ANALYSIS; MICRORNAS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASTIC STEM CELLS; ONCOGENES; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 80051545445     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.04.027     Document Type: Article

References (90)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2 2005 74 108 (Pubitemid 40372904)
2. F.X. Bosch, J. Ribes, M. Diaz, and R. Cleries Primary liver cancer: worldwide incidence and trends Gastroenterology 127 5 Suppl. 1 2004 S5 S16
3. L. Libbrecht, V. Desmet, and T. Roskams Preneoplastic lesions in human hepatocarcinogenesis Liver Int 25 1 2005 16 27 (Pubitemid 40298240)
4. S.S. Thorgeirsson, and J.W. Grisham Molecular pathogenesis of human hepatocellular carcinoma Nat Genet 31 4 2002 339 346 (Pubitemid 35154440)
5. S.W. Nam, J.Y. Park, and A. Ramasamy Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling Hepatology 42 4 2005 809 818 (Pubitemid 41401118)
6. P.A. Farazi, and R.A. DePinho Hepatocellular carcinoma pathogenesis: from genes to environment Nat Rev Cancer 6 9 2006 674 687 (Pubitemid 44286000)
7. K. Okuda Hepatocellular carcinoma J Hepatol 32 1 Suppl. 2000 225 237 (Pubitemid 30123637)
8. M.P. Bralet, J.M. Regimbeau, and P. Pineau Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases Hepatology 32 2 2000 200 204 (Pubitemid 30616011)
9. M. Ozturk P53 mutation in hepatocellular carcinoma after aflatoxin exposure Lancet 338 8779 1991 1356 1359
10. J.M. Llovet, J. Bustamante, and A. Castells Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials Hepatology 29 1 1999 62 67 (Pubitemid 29023987)
11. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 10 2008 698 711
12. L. Di Tommaso, A. Destro, and J.Y. Seok The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma J Hepatol 50 4 2009 746 754
13. P. Bioulac-Sage, S. Rebouissou, and C. Thomas Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry Hepatology 46 3 2007 740 748 (Pubitemid 47436120)
14. J. Zucman-Rossi, E. Jeannot, and J.T. Nhieu Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC Hepatology 43 3 2006 515 524
15. S. Rebouissou, M. Amessou, and G. Couchy Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours Nature 457 7226 2009 200 204
16. K. Minouchi, S. Kaneko, and K. Kobayashi Mutation of p53 gene in regenerative nodules in cirrhotic liver J Hepatol 37 2 2002 231 239 (Pubitemid 34833085)
17. B. Bressac, M. Kew, J. Wands, and M. Ozturk Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa Nature 350 6317 1991 429 431 (Pubitemid 21912246)
18. P. Laurent-Puig, and J. Zucman-Rossi Genetics of hepatocellular tumors Oncogene 25 27 2006 3778 3786 (Pubitemid 43980473)
19. Y. Miyoshi, K. Iwao, and Y. Nagasawa Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3 Cancer Res 58 12 1998 2524 2527 (Pubitemid 28275419)
20. Y. Ishizaki, S. Ikeda, and M. Fujimori Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas Int J Oncol 24 5 2004 1077 1083
21. S. Satoh, Y. Daigo, and Y. Furukawa AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 Nat Genet 24 3 2000 245 250 (Pubitemid 30132191)
22. Y.J. Yao, X.L. Ping, and H. Zhang PTEN/MMAC1 mutations in hepatocellular carcinomas Oncogene 18 20 1999 3181 3185 (Pubitemid 29261240)
23. M. Weihrauch, M. Benicke, and G. Lehnert Frequent k-ras-2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride Br J Cancer 84 7 2001 982 989 (Pubitemid 32385844)
24. Y. Murakami, K. Hayashi, S. Hirohashi, and T. Sekiya Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas Cancer Res 51 20 1991 5520 5525
25. C.T. Liew, H.M. Li, and K.W. Lo High frequency of p16INK4A gene alterations in hepatocellular carcinoma Oncogene 18 3 1999 789 795 (Pubitemid 29080337)
26. A.T. De Souza, G.R. Hankins, M.K. Washington, T.C. Orton, and R.L. Jirtle M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity Nat Genet 11 4 1995 447 449
27. C. Martins, M.A. Kedda, and M.C. Kew Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks World J Gastroenterol 5 6 1999 470 476
28. M. Jin, Z. Piao, and N.G. Kim P16 is a major inactivation target in hepatocellular carcinoma Cancer 89 1 2000 60 68 (Pubitemid 30451274)
29. J.W. Lee, Y.H. Soung, and S.Y. Kim PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas Oncogene 24 8 2005 1477 1480 (Pubitemid 40343128)
30. W. Yan, Y. Fu, and D. Tian PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells Biochem Biophys Res Commun 382 3 2009 631 636
31. J.P. Thiery Epithelial-mesenchymal transitions in tumour progression Nat Rev Cancer 2 6 2002 442 454
32. A. Villanueva, D.Y. Chiang, and P. Newell Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 6 2008 1972 1983 1983 e1-e11
33. Y. Tanaka, F. Kanai, and M. Tada Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients Oncogene 25 20 2006 2950 2952 (Pubitemid 43739246)
34. J.S. Lee, I.S. Chu, and J. Heo Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling Hepatology 40 3 2004 667 676 (Pubitemid 39265589)
35. J.S. Lee, J. Heo, and L. Libbrecht A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells Nat Med 12 4 2006 410 416
36. S. Boyault, D.S. Rickman, and A. de Reynies Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets Hepatology 45 1 2007 42 52 (Pubitemid 46144363)
37. D.Y. Chiang, A. Villanueva, and Y. Hoshida Focal gains of VEGFA and molecular classification of hepatocellular carcinoma Cancer Res 68 16 2008 6779 6788
38. K. Breuhahn, S. Vreden, and R. Haddad Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression Cancer Res 64 17 2004 6058 6064 (Pubitemid 39129404)
39. N. Iizuka, M. Oka, and H. Yamada-Okabe Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection Lancet 361 9361 2003 923 929 (Pubitemid 36332108)
40. S.M. Wang, L.L. Ooi, and K.M. Hui Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma Clin Cancer Res 13 21 2007 6275 6283 (Pubitemid 350075015)
41. H.G. Woo, E.S. Park, and J.H. Cheon Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma Clin Cancer Res 14 7 2008 2056 2064 (Pubitemid 351551116)
42. Q.H. Ye, L.X. Qin, and M. Forgues Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning Nat Med 9 4 2003 416 423 (Pubitemid 36460075)
43. P. Kaposi-Novak, J.S. Lee, and L. Gomez-Quiroz Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype J Clin Invest 116 6 2006 1582 1595
44. C. Coulouarn, V.M. Factor, and S.S. Thorgeirsson Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer Hepatology 47 6 2008 2059 2067 (Pubitemid 351945572)
45. Y. Hoshida, S.M. Nijman, and M. Kobayashi Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Cancer Res 69 18 2009 7385 7392
46. H. van Malenstein, O. Gevaert, and L. Libbrecht A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma Clin Cancer Res 16 16 2010 4278 4288
47. Y. Hoshida, A. Villanueva, and M. Kobayashi Gene expression in fixed tissues and outcome in hepatocellular carcinoma N Engl J Med 359 19 2008 1995 2004
48. A. Budhu, M. Forgues, and Q.H. Ye Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment Cancer Cell 10 2 2006 99 111 (Pubitemid 44202603)
49. T. Roskams Liver stem cells and their implication in hepatocellular and cholangiocarcinoma Oncogene 25 27 2006 3818 3822 (Pubitemid 43980477)
50. T. Reya, S.J. Morrison, M.F. Clarke, and I.L. Weissman Stem cells, cancer, and cancer stem cells Nature 414 6859 2001 105 111 (Pubitemid 33041634)
51. L.L. Campbell, and K. Polyak Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6 19 2007 2332 2338 (Pubitemid 350058682)
52. T.A. Roskams, N.D. Theise, and C. Balabaud Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers Hepatology 39 6 2004 1739 1745 (Pubitemid 38702678)
53. T.G. Bird, S. Lorenzini, and S.J. Forbes Activation of stem cells in hepatic diseases Cell Tissue Res 331 1 2008 283 300 (Pubitemid 50005924)
54. A. Durnez, C. Verslype, and F. Nevens The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin Histopathology 49 2 2006 138 151 (Pubitemid 44079697)
55. T. Uenishi, S. Kubo, and T. Yamamoto Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence Cancer Sci 94 10 2003 851 857 (Pubitemid 37406966)
56. X.R. Yang, Y. Xu, and G.M. Shi Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection Clin Cancer Res 14 12 2008 3850 3859
57. T. Yamashita, M. Forgues, and W. Wang EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma Cancer Res 68 5 2008 1451 1461 (Pubitemid 351346853)
58. P. Laurent-Puig, P. Legoix, and O. Bluteau Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis Gastroenterology 120 7 2001 1763 1773 (Pubitemid 32523494)
59. I. Dvorchik, M. Schwartz, M.I. Fiel, S.D. Finkelstein, and J.W. Marsh Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma Liver Transpl 14 4 2008 443 450 (Pubitemid 351524399)
60. R.R. Plentz, M. Caselitz, and J.S. Bleck Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma Hepatology 40 1 2004 80 86 (Pubitemid 38868926)
61. R.R. Plentz, B. Schlegelberger, and P. Flemming Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma Hepatology 42 3 2005 522 526 (Pubitemid 41233641)
62. Y. Urabe, K. Nouso, and T. Higashi Telomere length in human liver diseases Liver 16 5 1996 293 297 (Pubitemid 26388119)
63. P.A. Farazi, J. Glickman, and S. Jiang Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma Cancer Res 63 16 2003 5021 5027 (Pubitemid 37022640)
64. M.J. Ferber, D.P. Montoya, and C. Yu Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers Oncogene 22 24 2003 3813 3820 (Pubitemid 36760744)
65. Y. Maeta, G. Shiota, J. Okano, and Y. Murawaki Effect of promoter methylation of the p16 gene on phosphorylation of retinoblastoma gene product and growth of hepatocellular carcinoma cells Tumour Biol 26 6 2005 300 305 (Pubitemid 41619460)
66. I.H. Wong, Y.M. Lo, and J. Zhang Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients Cancer Res 59 1 1999 71 73 (Pubitemid 29062959)
67. Y. Matsuda, T. Ichida, J. Matsuzawa, K. Sugimura, and H. Asakura P16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma Gastroenterology 116 2 1999 394 400 (Pubitemid 29055363)
68. D.F. Calvisi, S. Ladu, and A. Gorden Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma J Clin Invest 117 9 2007 2713 2722 (Pubitemid 47494371)
69. D. Steinemann, B. Skawran, and T. Becker Assessment of differentiation and progression of hepatic tumors using array-based comparative genomic hybridization Clin Gastroenterol Hepatol 4 10 2006 1283 1291 (Pubitemid 44512219)
70. P. Moinzadeh, K. Breuhahn, H. Stutzer, and P. Schirmacher Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade - results of an explorative CGH meta-analysis Br J Cancer 92 5 2005 935 941 (Pubitemid 40462642)
71. H. Katoh, H. Ojima, and A. Kokubu Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets Gastroenterology 133 5 2007 1475 1486 (Pubitemid 350029748)
72. M.A. Patil, I. Gutgemann, and J. Zhang Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma Carcinogenesis 26 12 2005 2050 2057 (Pubitemid 41672192)
73. A. Esquela-Kerscher, and F.J. Slack Oncomirs - microRNAs with a role in cancer Nat Rev Cancer 6 4 2006 259 269
74. T. Xu, Y. Zhu, and Y. Xiong MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells Hepatology 50 1 2009 113 121
75. L. Gramantieri, F. Fornari, and E. Callegari MicroRNA involvement in hepatocellular carcinoma J Cell Mol Med 12 6A 2008 2189 2204
76. C. Coulouarn, V.M. Factor, J.B. Andersen, M.E. Durkin, and S.S. Thorgeirsson Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties Oncogene 28 40 2009 3526 3536
77. H. Su, J.R. Yang, and T. Xu MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity Cancer Res 69 3 2009 1135 1142
78. Y. Ladeiro, G. Couchy, and C. Balabaud MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations Hepatology 47 6 2008 1955 1963 (Pubitemid 351952843)
79. A. Budhu, H.L. Jia, and M. Forgues Identification of metastasis-related microRNAs in hepatocellular carcinoma Hepatology 47 3 2008 897 907 (Pubitemid 351449681)
80. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 19 2004 7099 7109 (Pubitemid 39331023)
81. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 4 2008 378 390
82. A.L. Cheng, Y.K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 1 2009 25 34
83. P. Newell, S. Toffanin, and A. Villanueva Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo J Hepatol 51 4 2009 725 733
84. P. Carmeliet Angiogenesis in life, disease and medicine Nature 438 7070 2005 932 936 (Pubitemid 43093958)
85. A. Subramanian, P. Tamayo, and V.K. Mootha Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles Proc Natl Acad Sci USA 102 43 2005 15545 15550 (Pubitemid 41528093)
86. E. Wurmbach, Y.B. Chen, and G. Khitrov Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma Hepatology 45 4 2007 938 947 (Pubitemid 46646500)
87. Y. Kurokawa, R. Matoba, and I. Takemasa Molecular-based prediction of early recurrence in hepatocellular carcinoma J Hepatol 41 2 2004 284 291 (Pubitemid 39177633)
88. X. Chen, S.T. Cheung, and S. So Gene expression patterns in human liver cancers Mol Biol Cell 13 6 2002 1929 1939 (Pubitemid 34651483)
89. P.V. Korita, T. Wakai, and Y. Shirai Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma Hum Pathol 39 12 2008 1777 1783
90. H. Okabe, S. Satoh, and T. Kato Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression Cancer Res 61 5 2001 2129 2137 (Pubitemid 32692038)